EXEL: SEC Form 8-K filed by Exelixis Inc.
Stocks in this Quantisnow insightHealth Care
Full content unavailable. See the original source below.
Historical context for EXEL
Across the 29 sessions after earlier EXEL headlines, the stock closed higher 18 times and lower 11 times, with a median move of 2.1% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | EXEL | SPY |
|---|---|---|---|
| Oct 30, 2026 | Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update | +4.8% | -1.8% |
| Oct 16, 2026 | Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026 | -1.0% | -1.1% |
| Sep 2, 2026 | Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September | +2.9% | +0.4% |
| Aug 31, 2026 | Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories | +0.3% | -0.3% |
| Aug 19, 2026 | BMO Capital Markets initiated coverage on Exelixis with a new price target | +2.4% | +0.2% |
| Aug 6, 2026 | Exelixis downgraded by Leerink Partners with a new price targetand 1 other headline that session | -7.9% | -0.2% |
Quantisnow market dataNASDAQ
EXEL
Exelixis Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2000
Get push alerts for EXEL
Full EXEL profile on Quantisnow Follow EXEL and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time